

Steven Isakoff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5591144/publications.pdf>

Version: 2024-02-01

19
papers

1,045
citations

933447

10
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

2343
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-23.	1.6	75
2	Abstract P3-09-11: Clinical characteristics associated with BRCA1/2 mutations identified on routine tumor tissue genotyping in metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P3-09-11-P3-09-11.	0.9	0
3	Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 993-1003.	7.0	21
4	Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast). <i>Breast Cancer Research and Treatment</i> , 2022, , .	2.5	5
5	Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study. <i>JCO Oncology Practice</i> , 2022, 18, e1447-e1453.	2.9	3
6	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3404-3413.	7.0	10
7	Abstract PS18-19: Comparison of metastatic genomic profile in patients ≤ 45 years and patients >45 years with triple-negative breast cancer. , 2021, , .		0
8	Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. <i>JCO Precision Oncology</i> , 2021, 5, 896-903.	3.0	6
9	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4883-4897.	7.0	11
10	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	1.6	76
11	Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2021, 11, 2436-2445.	9.4	69
12	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , 1-8.	4.9	36
13	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1246-1262.	3.0	16
14	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. <i>Npj Precision Oncology</i> , 2019, 3, 18.	5.4	25
15	Secondary Use of Patient Tissue in Cancer Biobanks. <i>Oncologist</i> , 2019, 24, 1577-1583.	3.7	5
16	LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1009-1009.	1.6	3
17	Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 287-297.	2.5	26
18	Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. <i>Journal of Clinical Oncology</i> , 2015, 33, 3621-3627.	1.6	172

#	ARTICLE	IF	CITATIONS
19	Convergent loss of PTEN leads to clinical resistance to a PI(3)K± inhibitor. Nature, 2015, 518, 240-244.	27.8	486